Table 2.
Comparison of Best corrected visual acuity of eyes receiving anti-VEGF
| Parameters | AMD | DME | RVO | Others | Overall |
|---|---|---|---|---|---|
| BCVA Group A | |||||
| Median | 0.8 (6/38) | 0.5 (6/19) | 0.6 (6/24) | 0.8 (6/38) | 0.6 (6/24) |
| IQR | 0.5-1 | 0.3-0.8 | 0.3-1 | 0.2-1 | 0.3-1 |
| Baseline BCVA Group B | |||||
| Median | 0.3 (6/12) | 0.3 (6/12) | 0.3 (6/12) | 0.9 (6/60) | 0.3 (6/12) |
| IQR | 0.2-0.6 | 0.2-0.6 | 0.2-0.6 | 0.7-1 | 0.2-0.6 |
| BCVA at prior visit Group B | |||||
| Median | 0.4 (6/15) | 0.3 (6/12) | 0.5 (6/19) | 0.9 (6/48) | 0.3 (6/12) |
| IQR | 0.2-0.6 | 0.2-0.6 | 0.2-1 | 0.8-1 | 0.2-0.6 |
| BCVA at current visit Group B | |||||
| Median | 0.5 (6/19) | 0.3 (6/12) | 0.5 (6/19) | 1 (6/60) | 0.5 (6/19) |
| IQR | 0.3-0.9 | 0.3-0.6 | 0.3-0.8 | 0.9-1 | 0.3-0.8 |
| Comparison of vision Group B at prior and current visit | 0.036* | 0.113* | 0.447* | 0.391# | 0.009* |
| Comparison of vision between Group A and Group B at baseline | 0.0002@ | 0.005@ | 0.007@ | 0.564$ | <0.001@ |
*Wilcoxon signed rank test; #paired t-test; S - Significant; @Mann-Whitney U test; $Independent; t-test; IQR - Inter quartile Range. Group A - Treatment Naïve eyes. Group B - Eyes that had received prior treatment and now reported for retreatment. All visual acuities are reported in LogMAR